The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment.

ABSTRACT:

Background

Serial profiling of circulating tumor DNA (ctDNA) could reflect dynamic molecular changes in response to treatment and potentially predict impending disease progression (PD). Herein, we investigated the molecular factors and dynamic changes in ctDNA that can serve as predictors of survival outcomes of patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) who received osimertinib therapy after progression from prior EGFR inhibitor regimen.

Methods

Capture-based targeted sequencing was performed on the baseline and longitudinal plasma samples collected from 72 and 57 patients, respectively, using a 168-gene panel.

Results

Analysis revealed that inferior overall survival (OS) was correlated with variou

SUBMITTER: Ma S 

PROVIDER: S-EPMC7867761 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature